NCT05438641View on ClinicalTrials.gov

Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Alcohol Withdrawal Syndrome
Interventions
DRUG

BZDP-Sparing Protocol

BZDP-Sparing group includes subjects primarily treated with a non-BZDP agent (e.g., Alpha-2 agonists and/or anticonvulsants). Rescue with BZDP-based treatment allowed if there is symptomatic breakthrough- as measured by CIWA \> 15.

DRUG

BZDP-Based Protocol

Patients in this arm will received active treatment based on conventional BZDP-based protocol; additional BZDP are permitted for patients who are still symptomatic, based on CIWA-Protocol.

Trial Locations (1)

94305

Stanford Hospital and Clinics, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT05438641 - Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants | Biotech Hunter | Biotech Hunter